A fund and its general partner report the same 1.49M BlossomHill (BLSM) shares.
Alpha Vantage · Stock Titan · · AI-summarised by FinFlash
Vivo Innovation Fund II Holdings, L.P. and its general partner, Vivo Innovation II, LLC, have filed an amended Schedule 13G, reporting beneficial ownership of 1,493,740 shares of BlossomHill Therapeutics, Inc. (BLSM). This represents a 4.7% stake in the company, with both entities reporting sole voting and dispositive power over the same position.
Understand the context
Published information may change. Summaries can contain errors; check the original source. Educational information only, not investment advice.